Enzyme infusion aimed at taming sepsis enters first human safety trial
NCT ID NCT05453695
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether an intravenous enzyme called DNase I is safe and feasible for ICU patients with sepsis. Sepsis is a life-threatening response to infection that can damage organs. The study will enroll 36 adults and monitor how many complete the treatment and blood collection as planned. It is a first step to see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNase I (an enzyme given intravenously)
What this could lead to
If safe and feasible, this could pave the way for a new treatment to reduce organ damage in sepsis.
What could go wrong
This is a very early phase 1 trial with only 36 patients, focused on safety, not effectiveness. It may not show benefit or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hamilton Health Sciences
RECRUITINGHamilton, Ontario, L8L 0A4, Canada
Contact